Malignant Prostate Neoplasm — Trials

Malignant Prostate Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

5,977 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,375
Recruiting: 744
Ph III recruiting: 79
Growth YoY: +22.9%
Industry share: 18%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 27.1%
Trials / 1,000 deaths: 40.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (730)

clinicaltrialsPublishedShowing 1–31 of 31 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04071236	Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy	suspended	Phase 1 / Phase 2	90	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT06144619	Non-Invasive Biomarkers in Prostate Cancer Disease Management	suspended	—	500	H. Lee Moffitt Cancer Center and Research InstituteOTHER